- Sanofi Canada will make Nuvaxovid, a protein-based, non-mRNA COVID-19 vaccine, available across all 10 provinces and Yukon for the 2026–2027 respiratory season through public programs and most private insurers.
- The vaccine offers Canadians an additional option alongside mRNA vaccines, supporting vaccination choices based on individual preferences and healthcare provider recommendations. It is indicated for individuals aged 12 and older.
- Nuvaxovid demonstrated approximately 90% efficacy against symptomatic COVID-19 in pivotal Phase III clinical trials and has shown a favourable tolerability profile for seasonal vaccination.
- Its expanded availability comes amid continued COVID-19 burden in Canada, including more than 120,000 reported cases, 33,500 hospitalizations, and 2,300 deaths during the 2024–2025 respiratory season.
Takeaways:
Nuvaxovid’s availability across 10 provinces and Yukon strengthens Sanofi’s position in Canada’s seasonal COVID-19 vaccine market by expanding access to a protein-based, non-mRNA alternative. Its established technology platform may appeal to Canadians seeking vaccine choice, including immunocompromised populations. Uptake will depend on public program access, provider recommendations and competition from mRNA vaccines.
Source: CA Newswire
